Research programme: anti-hypertensive therapy - Pfizer

Drug Profile

Research programme: anti-hypertensive therapy - Pfizer

Latest Information Update: 06 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Heterocyclic compounds
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Hypertension

Most Recent Events

  • 05 Aug 2009 Preclinical development is ongoing in USA
  • 10 Apr 2006 Preclinical trials in Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top